Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of EGRX stock opened at $0.80 on Friday. The stock’s 50-day moving average price is $0.68 and its 200 day moving average price is $2.22. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.81.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in EGRX. Cubist Systematic Strategies LLC acquired a new position in shares of Eagle Pharmaceuticals in the second quarter worth $145,000. Mackenzie Financial Corp acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $65,000. Creative Planning acquired a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $59,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $453,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.